Mitwally, M. F., & Casper, R. F. (2002). Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertility and Sterility, 77(4), 776-780. https://doi.org/10.1016/s0015-0282(01)03280-0
Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril. 2002;77(4):776-780. doi:10.1016/s0015-0282(01)03280-0
Mitwally, Mohamed Farouk M., and Robert F. Casper. "Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders." Fertility and Sterility, vol. 77, no. 4, 2002, pp. 776-780.
For EndNote, Zotero or Mendeley:
Open access
Free to read
No reuse license
Free to read at the publisher (reported by Unpaywall and OpenAlex, not verified by RRM Academy)
Author affiliations
2 institutions
Department of Obstetrics and Gynecology, University of Toronto, and The Samuel Lununfeld Research Institute, Mount Sinai Hospital, Toronto, Canada.
Poor responders had more mature follicles with letrozole plus FSH
Cycles with letrozole plus FSH had more mature follicles in women who responded poorly. This 2002 Toronto observational cohort study, a pilot trial, compared 20 FSH-only cycles with 14 letrozole cycles in 12 women with unexplained infertility. Three of the 14 letrozole cycles ended in a clinical pregnancy.
Key Findings
Mean mature follicles were 3.3 in the 14 letrozole plus FSH cycles and 1.9 in the 20 completed FSH-only cycles (P = .003).
Letrozole cycles needed significantly less total FSH (P = .0001) and fewer stimulation days: 6.57 days versus 9 days (P = .026).
No pregnancy occurred in the FSH-only cycles. Four women became pregnant during letrozole plus FSH cycles: three clinical pregnancies (21%) and one chemical pregnancy.
Endometrial thickness on the day of hCG did not differ significantly between cycle types. Estradiol per mature follicle was significantly lower with letrozole (P = .0001).
Interpretation
The report is an observational cohort study run as a prospective pilot trial. Twelve women, aged 24 to 41, served as their own comparison, and the letrozole cycles followed their FSH-only cycles. The authors describe the design as nonrandomized and nonplacebo controlled. Five FSH-only cycles stopped for inadequate response. The statistics compared 20 cycles with 14 cycles drawn from the same 12 women. The authors call the report preliminary and describe a potential benefit. They state that the effect of a short letrozole course on pregnancy outcome is unknown.
RRM Context
The paper lists advanced age, prior ovarian surgery, severe endometriosis and pelvic infection as possible reasons for a low response. It adds that in most patients the reason stays unexplained. Restorative reproductive medicine treats an unexplained response as an undiagnosed one and looks for the cause. Drugs that raise follicle counts in one cycle leave that cause unaddressed.
Our editorial summary of this paper, not the article's abstract.
Abstract
Objective
To examine the use of the aromatase inhibitor letrozole with FSH for ovarian stimulation in poor responders undergoing ovarian superovulation and IUI.
Design
Observational cohort study as a prospective clinical trial in patients with unexplained infertility and a low response to ovarian stimulation with FSH.
Setting
Two tertiary referral infertility clinics associated with the Reproductive Sciences Division, University of Toronto.
Patients
Twelve patients with unexplained infertility undergoing IUI who received FSH alone in 25 prior cycles with poor response (less than three dominant follicles).
Interventions
Patients were offered letrozole, 2.5 mg/day from day 3-7 of the menstrual cycle with FSH (50-225 IU/day) starting on day 5-7. hCG (10,000 IU) was given when two leading follicles were >/=2 cm followed by IUI.
Main Outcome Measures
Number of mature follicles (>1.8 cm), FSH dose, endometrial thickness, and pregnancy rate.
Results
Improved response to FSH stimulation with letrozole co-treatment was evidenced by the significantly lower FSH dose associated with significantly higher number of mature follicles. During letrozole plus FSH stimulation cycles, clinical pregnancy was achieved in three cycles (21%).
Conclusions
In this preliminary report, we demonstrate a potential benefit of aromatase inhibition for improving ovarian response to FSH in poor responders.